{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:24:48Z","timestamp":1786980288640,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"17-18","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T00:00:00Z","timestamp":1567728000000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00508-019-01544-5","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T10:50:58Z","timestamp":1567767058000},"page":"395-403","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Patterns and prevalence of dyslipidemia in patients with different etiologies of chronic liver disease"],"prefix":"10.1007","volume":"131","author":[{"given":"Lukas W.","family":"Unger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"Forstner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Schneglberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Muckenhuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst","family":"Eigenbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Scheiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Mandorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4590-3583","authenticated-orcid":false,"given":"Thomas","family":"Reiberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,6]]},"reference":[{"issue":"10","key":"1544_CR1","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","volume":"135","author":"EJ Benjamin","year":"2017","unstructured":"Benjamin\u00a0EJ, Blaha\u00a0MJ, Chiuve\u00a0SE, Cushman\u00a0M, Das\u00a0SR, Deo\u00a0R, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146\u2013e603. \n                    https:\/\/doi.org\/10.1161\/CIR.0000000000000485\n                    \n                  .","journal-title":"Circulation"},{"issue":"1","key":"1544_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2013.10.030","volume":"232","author":"P Loria","year":"2014","unstructured":"Loria\u00a0P, Marchesini\u00a0G, Nascimbeni\u00a0F, Ballestri\u00a0S, Maurantonio\u00a0M, Carubbi\u00a0F, et al. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. Atherosclerosis. 2014;232(1):99\u2013109. \n                    https:\/\/doi.org\/10.1016\/j.atherosclerosis.2013.10.030\n                    \n                  .","journal-title":"Atherosclerosis"},{"key":"1544_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000001119","author":"M Salavrakos","year":"2018","unstructured":"Salavrakos\u00a0M, Piessevaux\u00a0H, Komuta\u00a0M, Lanthier\u00a0N, Starkel\u00a0P. Fibroscan reliably rules out advanced liver fibrosis and significant portal hypertension in alcoholic patients. J\u00a0Clin Gastroenterol. 2018; \n                    https:\/\/doi.org\/10.1097\/MCG.0000000000001119\n                    \n                  .","journal-title":"J Clin Gastroenterol"},{"issue":"3 Suppl","key":"1544_CR4","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jacl.2014.02.011","volume":"8","author":"H Bays","year":"2014","unstructured":"Bays\u00a0H, Cohen\u00a0DE, Chalasani\u00a0N, Harrison\u00a0SA, The National Lipid Association\u2019s Statin Safety Task F. An assessment by the statin liver safety task force: 2014 update. J\u00a0Clin Lipidol. 2014;8(3 Suppl):S47\u2013S57. \n                    https:\/\/doi.org\/10.1016\/j.jacl.2014.02.011\n                    \n                  .","journal-title":"J Clin Lipidol"},{"issue":"5","key":"1544_CR5","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1053\/j.gastro.2016.06.055","volume":"151","author":"RA Weersink","year":"2016","unstructured":"Weersink\u00a0RA, Drenth\u00a0JP, Borgsteede\u00a0SD. Altered pharmacokinetics of statins explain increased risk of rhabdomyolysis in advanced cirrhosis. Gastroenterology. 2016;151(5):1036. \n                    https:\/\/doi.org\/10.1053\/j.gastro.2016.06.055\n                    \n                  .","journal-title":"Gastroenterology"},{"issue":"2","key":"1544_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/MAJ.0b013e3181e15da8","volume":"340","author":"FS Rzouq","year":"2010","unstructured":"Rzouq\u00a0FS, Volk\u00a0ML, Hatoum\u00a0HH, Talluri\u00a0SK, Mummadi\u00a0RR, Sood\u00a0GK. Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians. Am J Med Sci. 2010;340(2):89\u201393. \n                    https:\/\/doi.org\/10.1097\/MAJ.0b013e3181e15da8\n                    \n                  .","journal-title":"Am J Med Sci"},{"issue":"5","key":"1544_CR7","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","volume":"136","author":"JG Abraldes","year":"2009","unstructured":"Abraldes\u00a0JG, Albillos\u00a0A, Banares\u00a0R, Turnes\u00a0J, Gonzalez\u00a0R, Garcia-Pagan\u00a0JC, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a\u00a0randomized controlled trial. Gastroenterology. 2009;136(5):1651\u20138. \n                    https:\/\/doi.org\/10.1053\/j.gastro.2009.01.043\n                    \n                  .","journal-title":"Gastroenterology"},{"issue":"11\u201312","key":"1544_CR8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00508-012-0190-5","volume":"124","author":"T Reiberger","year":"2012","unstructured":"Reiberger\u00a0T, Ferlitsch\u00a0A, Payer\u00a0BA, Pinter\u00a0M, Schwabl\u00a0P, Stift\u00a0J, et\u00a0al. Noninvasive screening for liver fibrosis and portal hypertension by transient elastography\u2014a large single center experience. Wien Klin Wochenschr. 2012;124(11\u201312):395\u2013402. \n                    https:\/\/doi.org\/10.1007\/s00508-012-0190-5\n                    \n                  .","journal-title":"Wien Klin Wochenschr"},{"issue":"2","key":"1544_CR9","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/liv.12623","volume":"35","author":"P Schwabl","year":"2015","unstructured":"Schwabl\u00a0P, Bota\u00a0S, Salzl\u00a0P, Mandorfer\u00a0M, Payer\u00a0BA, Ferlitsch\u00a0A, et\u00a0al. New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension. Liver Int. 2015;35(2):381\u201390. \n                    https:\/\/doi.org\/10.1111\/liv.12623\n                    \n                  .","journal-title":"Liver Int"},{"issue":"3","key":"1544_CR10","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","volume":"63","author":"R de Franchis","year":"2015","unstructured":"de Franchis\u00a0R, Baveno\u00a0VIF. Expanding consensus in portal hypertension: report of the baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J\u00a0Hepatol. 2015;63(3):743\u201352. \n                    https:\/\/doi.org\/10.1016\/j.jhep.2015.05.022\n                    \n                  .","journal-title":"J Hepatol"},{"issue":"Suppl 2","key":"1544_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP171764.APPGL","volume":"23","author":"PS Jellinger","year":"2017","unstructured":"Jellinger\u00a0PS, Handelsman\u00a0Y, Rosenblit\u00a0PD, Bloomgarden\u00a0ZT, Fonseca\u00a0VA, Garber\u00a0AJ, et\u00a0al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. Endocr Pract. 2017;23(Suppl 2):1\u201387. \n                    https:\/\/doi.org\/10.4158\/EP171764.APPGL\n                    \n                  .","journal-title":"Endocr Pract"},{"key":"1544_CR12","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.atherosclerosis.2018.01.012","volume":"269","author":"F Gragnano","year":"2018","unstructured":"Gragnano\u00a0F, Calabro\u00a0P. Role of dual lipid-lowering therapy in coronary atherosclerosis regression: evidence from recent studies. Atherosclerosis. 2018;269:219\u201328. \n                    https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.01.012\n                    \n                  .","journal-title":"Atherosclerosis"},{"key":"1544_CR13","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1146\/annurev.immunol.021908.132620","volume":"27","author":"E Galkina","year":"2009","unstructured":"Galkina\u00a0E, Ley\u00a0K. Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol. 2009;27:165\u201397. \n                    https:\/\/doi.org\/10.1146\/annurev.immunol.021908.132620\n                    \n                  .","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"1544_CR14","doi-asserted-by":"publisher","first-page":"e1005610","DOI":"10.1371\/journal.ppat.1005610","volume":"12","author":"S Yamamoto","year":"2016","unstructured":"Yamamoto\u00a0S, Fukuhara\u00a0T, Ono\u00a0C, Uemura\u00a0K, Kawachi\u00a0Y, Shiokawa\u00a0M, et\u00a0al. Lipoprotein receptors redundantly participate in entry of hepatitis C virus. PLoS Pathog. 2016;12(5):e1005610. \n                    https:\/\/doi.org\/10.1371\/journal.ppat.1005610\n                    \n                  .","journal-title":"PLoS Pathog"},{"issue":"1","key":"1544_CR15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.5604\/01.3001.0010.7536","volume":"17","author":"S Gitto","year":"2018","unstructured":"Gitto\u00a0S, Cicero\u00a0AFG, Loggi\u00a0E, Giovannini\u00a0M, Conti\u00a0F, Grandini\u00a0E, et\u00a0al. Worsening of serum lipid profile after direct acting antiviral treatment. Ann Hepatol. 2018;17(1):64\u201375. \n                    https:\/\/doi.org\/10.5604\/01.3001.0010.7536\n                    \n                  .","journal-title":"Ann Hepatol"},{"issue":"2","key":"1544_CR16","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.atherosclerosis.2010.03.008","volume":"211","author":"CH Wang","year":"2010","unstructured":"Wang\u00a0CH, Chen\u00a0CJ, Lee\u00a0MH, Yang\u00a0HI, Hsiao\u00a0CK. Chronic hepatitis B infection and risk of atherosclerosis-related mortality: a 17-year follow-up study based on 22,472 residents in Taiwan. Atherosclerosis. 2010;211(2):624\u20139. \n                    https:\/\/doi.org\/10.1016\/j.atherosclerosis.2010.03.008\n                    \n                  .","journal-title":"Atherosclerosis"},{"issue":"4","key":"1544_CR17","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/MOL.0b013e32833c1f41","volume":"21","author":"EA Brinton","year":"2010","unstructured":"Brinton\u00a0EA. Effects of ethanol intake on lipoproteins and atherosclerosis. Curr Opin Lipidol. 2010;21(4):346\u201351. \n                    https:\/\/doi.org\/10.1097\/MOL.0b013e32833c1f41\n                    \n                  .","journal-title":"Curr Opin Lipidol"},{"issue":"1","key":"1544_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1373\/clinchem.2008.108720","volume":"55","author":"KF Foley","year":"2009","unstructured":"Foley\u00a0KF, Silveira\u00a0MG, Hornseth\u00a0JM, Lindor\u00a0KD, McConnell\u00a0JP. A patient with primary biliary cirrhosis and elevated LDL cholesterol. Clin Chem. 2009;55(1):187\u201391. \n                    https:\/\/doi.org\/10.1373\/clinchem.2008.108720\n                    \n                  . disscusion 191\u2013182.","journal-title":"Clin Chem"},{"issue":"11","key":"1544_CR19","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1194\/jlr.M400229-JLR200","volume":"45","author":"PY Chang","year":"2004","unstructured":"Chang\u00a0PY, Lu\u00a0SC, Su\u00a0TC, Chou\u00a0SF, Huang\u00a0WH, Morrisett\u00a0JD, et al. Lipoprotein\u2011X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation. J\u00a0Lipid Res. 2004;45(11):2116\u201322. \n                    https:\/\/doi.org\/10.1194\/jlr.M400229-JLR200\n                    \n                  .","journal-title":"J Lipid Res"},{"issue":"14","key":"1544_CR20","doi-asserted-by":"publisher","first-page":"6919","DOI":"10.1128\/JVI.76.14.6919-6928.2002","volume":"76","author":"P Andre","year":"2002","unstructured":"Andre\u00a0P, Komurian-Pradel\u00a0F, Deforges\u00a0S, Perret\u00a0M, Berland\u00a0JL, Sodoyer\u00a0M, et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J\u00a0Virol. 2002;76(14):6919\u201328.","journal-title":"J Virol"},{"issue":"2","key":"1544_CR21","first-page":"586","volume":"126","author":"A Lonardo","year":"2004","unstructured":"Lonardo\u00a0A, Adinolfi\u00a0LE, Loria\u00a0P, Carulli\u00a0N, Ruggiero\u00a0G, Day\u00a0CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Baillieres Clin Gastroenterol. 2004;126(2):586\u201397.","journal-title":"Baillieres Clin Gastroenterol"},{"key":"1544_CR22","doi-asserted-by":"publisher","first-page":"42710","DOI":"10.1038\/srep42710","volume":"7","author":"T Wu","year":"2017","unstructured":"Wu\u00a0T, Zheng\u00a0X, Yang\u00a0M, Zhao\u00a0A, Li\u00a0M, Chen\u00a0T, et al. Serum lipid alterations identified in chronic hepatitis B, hepatitis B virus-associated cirrhosis and carcinoma patients. Sci Rep. 2017;7:42710. \n                    https:\/\/doi.org\/10.1038\/srep42710\n                    \n                  .","journal-title":"Sci Rep"},{"issue":"7","key":"1544_CR23","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.cgh.2013.08.014","volume":"12","author":"KE Corey","year":"2014","unstructured":"Corey\u00a0KE, Chalasani\u00a0N. Management of dyslipidemia as a\u00a0cardiovascular risk factor in individuals with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12(7):1077\u201384. \n                    https:\/\/doi.org\/10.1016\/j.cgh.2013.08.014\n                    \n                  . quiz e1059\u20131060.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1544_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.04.013","author":"Y Gepner","year":"2019","unstructured":"Gepner\u00a0Y, Shelef\u00a0I, Komy\u00a0O, Cohen\u00a0N, Schwarzfuchs\u00a0D, Bril\u00a0N, et al. The beneficial effects of mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content. J\u00a0Hepatol. 2019; \n                    https:\/\/doi.org\/10.1016\/j.jhep.2019.04.013\n                    \n                  .","journal-title":"J Hepatol"},{"issue":"5","key":"1544_CR25","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","volume":"66","author":"T Karlas","year":"2017","unstructured":"Karlas\u00a0T, Petroff\u00a0D, Sasso\u00a0M, Fan\u00a0JG, Mi\u00a0YQ, de Ledinghen\u00a0V, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J\u00a0Hepatol. 2017;66(5):1022\u201330. \n                    https:\/\/doi.org\/10.1016\/j.jhep.2016.12.022\n                    \n                  .","journal-title":"J Hepatol"},{"issue":"1","key":"1544_CR26","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/hep.28709","volume":"65","author":"JP Arab","year":"2017","unstructured":"Arab\u00a0JP, Karpen\u00a0SJ, Dawson\u00a0PA, Arrese\u00a0M, Trauner\u00a0M. Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Hepatology. 2017;65(1):350\u201362. \n                    https:\/\/doi.org\/10.1002\/hep.28709\n                    \n                  .","journal-title":"Hepatology"},{"issue":"2","key":"1544_CR27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1136\/gut.51.2.265","volume":"51","author":"M Longo","year":"2002","unstructured":"Longo\u00a0M, Crosignani\u00a0A, Battezzati\u00a0PM, Squarcia Giussani\u00a0C, Invernizzi\u00a0P, Zuin\u00a0M, et\u00a0al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut. 2002;51(2):265\u20139.","journal-title":"Gut"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-019-01544-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00508-019-01544-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-019-01544-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T19:33:14Z","timestamp":1599247994000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00508-019-01544-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":27,"journal-issue":{"issue":"17-18","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["1544"],"URL":"https:\/\/doi.org\/10.1007\/s00508-019-01544-5","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"22 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.W.\u00a0Unger, B.\u00a0Forstner, S.\u00a0Schneglberger, M.\u00a0Muckenhuber, E.\u00a0Eigenbauer, and B.\u00a0Scheiner, declare that they have no competing interests. M.\u00a0Mandorfer has served as a\u00a0speaker and\/or consultant and\/or advisory board member for AbbVie, Bristol-Myers Squibb, Gilead, W. L. Gore & Associates, and Janssen. M.\u00a0Trauner has served as speaker for BMS, Falk Foundation, Gilead and MSD; advisory boards for Albireo, Falk Pharma GmbH, Genfit, Gilead, Intercept, MSD, Novartis, Phenex and Regulus. He further received travel grants from Abbvie, Falk, Gilead and Intercept and unrestricted research grants from Albireo, Cymabay, Falk, Gilead, Intercept, MSD and Takeda. He is also coinventor of patents on the medical use of norUDCA filed by the Medical University of Graz. T.\u00a0Reiberger has served as a\u00a0speaker and\/or consultant and\/or advisory board member for AbbVie, Bayer, Boehringer Ingelheim, Gilead, W. L. Gore & Associates, and MSD and has received research funding from AbbVie, Boehringer Ingelheim, Gilead, MSD, Phenex Pharmaceuticals, and Philips.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}